LEAN Mass Preservation With Resistance Exercise and Protein During Semaglutide/Tirzepatide Therapy

NANot yet recruitingINTERVENTIONAL
Enrollment

232

Participants

Timeline

Start Date

August 10, 2025

Primary Completion Date

August 30, 2029

Study Completion Date

December 31, 2029

Conditions
Obesity
Interventions
BEHAVIORAL

Resistance exercise

Participants assigned to the resistance exercise group will be asked to perform exercises 3 times a week for the intervention period. The first 3 sessions of the exercise will be performed under the supervision of a qualified exercise specialist to ensure that the participants are happy with the exercises and are performing them appropriately. These will also be group sessions to encourage participants to build social connections to support them during the intervention. A similar group social session will take place at week 4 and then every 4 weeks of the study to overcome any issues with the exercises and to ensure progression to an appropriate intensity.

DIETARY_SUPPLEMENT

Protein Intake

The aim of this arm of the intervention is to ensure a protein intake of 1.6g/kg/day, as this was the intake level identified as the level after which no further effect was found on muscle mass in the meta-regression from (Morton et al., 2018). For the initial 2 weeks of the study, we will ask participants to consume 2 protein drinks, containing 25g protein (3g leucine), per day - one in the morning and one in the evening. At this stage, we won't know the magnitude of reduction of protein intake following initiation of semaglutide/tirzepatide treatment. After 2 weeks, when the first assessment of dietary intake after beginning semaglutide/tirzepatide treatment occurs, the additional protein will be based on the amount required to ensure 1.6g/kg/day with an aim to spread protein evenly across the day and aim for at least 25g protein (3g leucine) per meal or snack.

COMBINATION_PRODUCT

Resistance exercise + protein intake

Participants in this arm will follow the above resistance exercise and protein intake interventions

All Listed Sponsors
collaborator

University of Glasgow

OTHER

lead

Dasman Diabetes Institute

OTHER

NCT06885736 - LEAN Mass Preservation With Resistance Exercise and Protein During Semaglutide/Tirzepatide Therapy | Biotech Hunter | Biotech Hunter